Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial

The AspireAssist is the first Food and Drug Administration –approved endoluminal device indicated for treatment of class II and III obesity.

Source: Surgery for Obesity and Related Diseases - May 1, 2019 Category: Surgery Authors: Christopher C. Thompson, Barham K. Abu Dayyeh, Vladimir Kushnir, Robert F. Kushner, Pichamol Jirapinyo, Alan B. Schorr, Louis J. Aronne, Anastassia Amaro, David L. Jaffe, Allison R. Schulman, Dayna Early, Adam C. Stein, Reem Sharaiha, Steven A. Edmundowic Tags: Original article Source Type: research